Gyros Protein Technologies and Abacus ALS Sign Distribution Agreement
Abacus will distribute Gyrolab™ immunoassay products in Australia and New Zealand
Uppsala, Sweden, 15th December 2016: Gyros Protein Technologies AB, a pioneer in automated nanoliter-scale immunoassays and leading provider of peptide synthesizers and reagents, announced today that it has appointed Abacus ALS as exclusive distributor of its immunoassay products in Australia and New Zealand. Abacus ALS, an ISO 9001: 2008 accredited organization, is one of Australia’s and New Zealand’s largest privately owned companies serving customers in the diagnostic pathology, research and healthcare education industries.
Established in March 2016 through the merger of Gyros AB and Protein Technologies, Inc., Gyros Protein Technologies AB combines Gyros’ microfluidics, systems development and immunoassay expertise with Protein Technologies’ deep knowledge in developing and manufacturing instruments for peptide synthesis. The Company provides customers an unrivaled range of peptide synthesis and bioanalytical tools for biotherapeutics discovery, development and bioprocessing. Abacus ALS will be responsible for sales and technical support for the products that form the Company’s nanoliter-scale immunoassay platform business, including the Gyrolab xP workstation, Gyrolab xPlore, Bioaffy CDs, Gyrolab kits, Rexxip buffers and related reagents and service. These products are used by scientists in leading pharmaceutical, biotech, CRO, and CMO companies for bioanalytical applications such as pharmacokinetics/pharmacodynamics, immunogenicity, and quantitating bioprocess-related impurities.
Peter Luk, Vice President Asia-Pacific, Gyros Protein Technologies, said: “Abacus ALS has a proven track record with over fifty years of experience in building successful partnerships and providing excellent service and technical support in the region. This strong market presence and reputation, make them an ideal distribution partner for our immunoassay products. We are pleased to be working with Abacus ALS to build our network of customers in Australia and New Zealand.”
Shayne Christensen, Chief Executive Officer, Abacus ALS, commented: “Our purpose is to connect our Australasian customers with innovative global suppliers, and we are delighted to represent Gyros Protein Technologies in our market.”
For a high resolution image please contact Zyme Communications
Peter Luk, Vice President Asia-Pacific, Gyros Protein Technologies
About Gyros Protein Technologies (For more information please click here)
Gyros Protein Technologies, enables peptide synthesis and bioanalytical solutions that help scientists increase biomolecule performance and productivity in research, drug discovery, pre-clinical and clinical development, and bioprocess applications. Our low to mid-scale peptide synthesizer platforms are the Tribute®, Prelude® X, Symphony® X, and Sonata®. These solutions and our chemistries deliver uncompromising purity, flexibility, and quality for discovery and pre-clinical studies of simple to complex multifunctional peptides. Proprietary high performance nanoliter-scale immunoassay platforms, Gyrolab™xP workstation and Gyrolab xPlore™, are used by scientists in leading pharmaceutical, biotech, CRO, and CMO companies for bioanalytical applications such as pharmacokinetics/pharmacodynamics, immunogenicity, and quantitating bioprocess-related impurities. Our peptide synthesis and bioanalytical solutions accelerate your discovery, development, and manufacturing of safer biotherapeutics.
About Abacus ALS (for more information please click here)
Abacus ALS is one of Australia and New Zealand’s largest privately owned companies serving customers in the diagnostic pathology, research and healthcare education industries.
As an ISO 9001: 2008 accredited organisation with over 50 years’ experience, Abacus ALS is dedicated to providing the highest quality products to meet the specialist needs of our customers.
The products we sell and support are chosen because of their worldwide recognition for quality and manufacturer excellence. Through our partnership with over 100 local and international suppliers we are not only providing customers with innovative and often niche products that they would otherwise have difficulty sourcing, but also offering ongoing technical service and support at a local level. Our key customers are private pathology laboratories, hospitals, research and educational institutions, blood donor services, and specialist centres such as IVF and veterinary laboratories.
Although represented locally in major Australian and New Zealand cities, the Abacus ALS head office is in Brisbane, Queensland. Strategic objectives include company sustainability and developing people through fostering a high performance culture. The business is therefore constantly working to improve and to better serve and meet our customers’ needs.